Advertisement
UK markets open in 5 hours 52 minutes

  • NIKKEI 225

    37,974.05
    -486.03 (-1.26%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • CRUDE OIL

    82.75
    -0.06 (-0.07%)
     

  • GOLD FUTURES

    2,330.40
    -8.00 (-0.34%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • Bitcoin GBP

    51,822.15
    -1,791.35 (-3.34%)
     

  • CMC Crypto 200

    1,394.27
    -29.83 (-2.09%)
     

  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     

  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

Zacks Equity Research
Updated
BancorpSouth (BXS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Investors focused on the Medical space have likely heard of Editas Medicine (EDIT), but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.

Editas Medicine is a member of the Medical sector. This group includes 763 individual stocks and currently holds a Zacks Sector Rank of #11. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. EDIT is currently sporting a Zacks Rank of #2 (Buy).

Over the past three months, the Zacks Consensus Estimate for EDIT's full-year earnings has moved 0.33% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.

ADVERTISEMENT

According to our latest data, EDIT has moved about 23.43% on a year-to-date basis. Meanwhile, stocks in the Medical group have lost about 0.38% on average. This means that Editas Medicine is performing better than its sector in terms of year-to-date returns.

Looking more specifically, EDIT belongs to the Medical - Biomedical and Genetics industry, which includes 282 individual stocks and currently sits at #165 in the Zacks Industry Rank. This group has lost an average of 5.49% so far this year, so EDIT is performing better in this area.

Going forward, investors interested in Medical stocks should continue to pay close attention to EDIT as it looks to continue its solid performance.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Editas Medicine, Inc. (EDIT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.